Curriculum Vitae
Sandra A Forman, M.A.
Date May 22, 2014
Contact Information
3410 Nancy Ellen Way
Owings Mills, MD 21117
Phone: 410-356-5433
Education
1964-1968 B.S, The City College of New York Mathematics 1968-1969 M.A. Columbia University Mathematical Statistics
1973-1977 Johns Hopkins University School of Hygiene and Public Health
Part-time work toward Ph.D. degree in Biostatistics and Epidemiology
Post Graduate Education and Training
1968-1969 Research Fellowship – Columbia University
Certifications
2006 Enrolled Agent
Employment History – Other Employment
1968 1969 Research Associate, Health and Hospital Planning Council of Southern
New York
1969 1972 Biomedical Statistician, Schering Corporation
1972 1974 Research Programmer Analyst, University of Maryland, Department of Social and Preventive Medicine, Division of Clinical Investigation
1974 1982 Statistician, University of Maryland, Department of Epidemiology and Preventive Medicine, Division of Clinical Investigation
1979 2010 Statistician/Study Manager/Principal Investigator, Maryland Medical Research Institute (MMRI)
1990 - 1995 Statistician/Study Manager, Clinical Trials & Surveys Corp. (C-TASC)
1993 - present Tax Preparer/Enrolled Agent, H&R Block
1998 - 2000 Statistician/Study Manager, Clinical Trials & Surveys Corp. (C-TASC)
2010 - 2013 Senior Statistician/Principal Investigator, Clinical Trials & Surveys Corp. (C-TASC)
2013-present Consultant/Editorial staff, Johns Hopkins University Bloomberg School of Public Health, CEVG Cochrane Collaboration
Professional Society Memberships
1969-present American Statistical Association
1982 – present Society for Clinical Trials
Honors and Awards
1968 Phi Beta Kappa, Member
Local and National Service
Reviewer for Controlled Clinical Trials
2003-2007 Member, Data and Safety Monitoring Board for Pain Management in Temporomandibular Joint Disorders(TMJ)
NHLBI Consultant site visitor for INTERMACS
Active Research Support
2013 – current Consultant/Editorial Assistant(15%) PI:Dickersin
Cochrane Eyes and Vision Group US Project
Grant U01 EYE020522,National Eye Institute, NIH
Completed Research Support
1974 1982 Study Manager/Statistician Study PI: Stamler
Coronary Drug Project (CDP) DCC PI: Canner
National Heart, Lung, and Blood Institute
1979 1984 Study Manager/Statistician PI: Klimt
International Mexiletine Placebo Antiarrhythmic
Coronary Trial (IMPACT)
1983 1990 Study Manager/Statistician/Deputy Director PI:Barton
Ticlopidine-Aspirin Stroke Study (TASS)
Appointed Deputy Director for TASS in 1986
1983 1992 Study Manager/Statistician Study PI: Braunwald
Thrombolysis in Myocardial Infarction (TIMI 1,2) DCC PI: Knatterud
National Heart, Lung, and Blood Institute
1987 1990 Study Manager/Statistician
Study of HA1A Human Monoclonal Antibody in
Patients with Severe Gram Negative Sepsis
1988 1992 CoPrincipal Investigator
Unstable Angina Study (UNSA)
1990 - 1995 Study Manager/Statistician
Lupus Plasmapheresis Study Group (LPSG)
1991 - 1995 Study Manager/Statistician
Asymptomatic Cardiac Ischemic Pilot (ACIP) Study PI: Conti
National Heart, Lung, and Blood Institute DCC PI: Knatterud
1991 - 1997 Study Manager/Statistician Study PI:Sheps
Psychophysiological Investigation of Myocardial Ischemia DCC PI:Knatterud
(PIMI) National Heart, Lung, and Blood Institute
1993 - 1995 Statistician
Study of Auriculin7 Anaritide in Acute Tubular Necrosis (SCIOS NOVA)
1995 - 1997 Statistician/Study Manager
Auriculin7 Anaritide in Oliguric ATN Study (SCIOS Inc.)
1995 - 1999 Statistician/Study Manager Study PI:Shulman
Study of Post-Menopausal Hormone Therapy DCC PI:Terrin
for Unstable Angina (PMHT)
National Heart, Lung, and Blood Institute
1995 - 1999 Statistician Study PI :Campeau
Post Coronary Artery in Bypass Graft (POST CABG) DCC PI:Knatterud
Studies, National Heart, Lung, and Blood Institute
1996 - 1999 Statistician/Study Manager Study PI:Aversano
Primary Angioplasty Trial (PAT) DCC PI:Knatterud
1996 - 1999 Statistician/Study Manager Study PI:Kasper
Randomized Study of the Efficacy of Physician DCC PI:Terrin
Extender-Assisted Protocolized Care in Heart Failure
Outpatients at High Risk for Hospital Readmission
(CHF Team Study), Johns Hopkins Private sponsor
1998 - 2000 Statistician/Study Manager Study PI:Lipshultz
Women and Infant Transmission Study (WITS). DCC PI:Thompson
National Heart, Lung, and Blood Institute, R01 HL78522
1999 - 2002 Statistician/Study Manager DCC PI:Thompson
Once Daily Aminoglycoside Cystic Fibrosis Trial (ODACT).
1999 - 2006 Statistician/Study Manager Study PI:Hochman
Occluded Artery Trial (OAT) DCC PI:Knatterud
National Heart, Lung, and Blood Institute, R01 HL62511
2000 - 2002 Statistician/Study Manager
Management of Early Pregnancy Failure (MEPF). DCC PI:Frederick
2001 -2008 Co-Investigator/Statistician/PI Study PI: Dzavik
An Angiographic Substudy of the Occluded Artery Trial DCC PI:Terrin
(TOSCA-2)
National Heart, Lung, and Blood Institute, U01 HL062257
Subcontract from University of Alberta
Appointed Principal Investigator May 2007.
2001 - 2005 Co-Investigator/Statistician Study PI: Schulman
Vascular Interaction with Age in Myocardial Infarction DCC PI:Terrin
(VINTAGE MI).
NIA via Johns Hopkins University School of Medicine (Subcontract)
2002 – 2008 Co-Investigator/Statistician/PI Study PI: Rashba
Electrophysiologic Effects of Late PCI Substudy of OAT DCC PI:Terrin
(OAT-EP)
National Heart, Lung, and Blood Institute,
Subcontract from University of Maryland
Appointed Principal Investigator May 2007.
2003 – 2011 Consultant Study PI:Carson
Transfusion Therapy Trial for Functional Outcomes in DCC PI:Terrin
Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)
National Heart, Lung, and Blood Institute, R01 HL074815
2004 – 2009 Statistician/Study Manager/Principal Investigator Study PI:Udelson
Myocardial Viability and Remodeling Substudy of the DCC PI:Terrin
Occluded Artery Trial (OAT-NUC)
National Heart, Lung, and Blood Institute,
Subcontract from Tufts University/New England Medical Center
Appointed Principal Investigator May 2007.
2006 – 2012 Statistician/Study Manager/ /Principal Investigator Study PI:Hochman
Occluded Artery Trial Long Term Follow-Up (OAT-LTFU) DCC PI:Knatterud
National Heart, Lung, and Blood Institute, U01HL062511
Appointed Deputy-PI May 2007,Appointed Principal Investigator May 2009. Moved study to C-TASC in June 2010.
2010 – 2012 Principal Investigator of DCC Study PI: Aversano
Atlantic C-PORT Trial of Elective Angioplasty
Randomization and Statistical Analysis Center
2011 – 2013 Statistician/Project Manager Study PI:Louis
The NICHD National Standard for Normal Fetal Growth DCC PI:Thompson Singleton and Twin Studies
Enice Kennedy Shriver National Institute of Child Health
and Human Development NICHD
2011 – 2013 Statistician/Project Manager/Principal Investigator Study PI:Nansel Cultivating Healthy Environments in Families with DCC PI:Thompson
Type 1 Diabetes (CHEF)
Enice Kennedy Shriver National Institute of Child Health
and Human Development NICHD
Publications
Peer-reviewed journal articles
1. The Coronary Drug Project Research Group: Clofibrate and Niacin in coronary heart disease. JAMA 1975; 231:36081.
2. The Coronary Drug Project Research Group: Aspirin in coronary heart disease. J Chron Dis 1976; 29:62542.
3. Gordon RS, Kahn HA, Forman S: Altitude and cerebrovascular death rates show apparent relationship. Stroke 1977; 8:274.
4. Gordon RS, Forman S, Canner PL, Berge K, Miller D: Gallbladder disease as a side effect of drugs influencing lipid metabolism experience in the Coronary Drug Project. New Engl J Med 1977; 296:118590.
5. Gordon RS, Danner RN, Forman S: Letter to editor. New Engl J Med 1977; 297:61.
6. The Coronary Drug Project Research Group: Clofibrate and gallbladder disease (letter to the editor). New Engl J Med 1978; 298:461.
7. The Coronary Drug Project Research Group: Estrogens and cancer(letter to the editor). JAMA 1978; 239:27589.
8. Stamler J, Forman S, Krol WF: The natural history of myocardial infarction in the Coronary Drug Project: Longterm prognostic importance of serum lipid levels. Am J Cardiol 1978; 42:48998.
9. Meinert CL, Forman S, Jacobs DR, Stamler J. for the Coronary Drug Project Research Group: Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. J Chron Dis 1979; 32:41525.
10. Canner PL, Forman SA, Prud'homme GJ, Berge KG, Stamler J: Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. New Engl J Med 1980; 303:103841.
11. Schlant RC, Forman S, Stamler J, Canner PL: The natural history of coronary heart disease: Prognostic factors after recovery from myocardial infarction in 2789 men The Five Year Findings of the Coronary Drug Project. Circulation 1982; 66:40114.
12. Klimt CR, Forman S: Secondary prevention of myocardial infarction with drugs. Israel Journal of Medical Sciences 1983; 19:46070.
13. Meinert CL, Heinz EC, Forman SA: Coronary Drug Project: Methods and Lessons of a Multicenter Clinical Trial. Chapter 6 "Role and methods of the Coordinating Center." Controlled Clinical Trials 1983; 4:35575.
14. Knatterud, GL, Forman, SA, Canner, PL: Coronary Drug Project: Methods and lessons of a multicenter clinical trial. Chapter 11 "Design of data forms." Controlled Clinical Trials 1983; 4:42940.
15. Canner PL, Krol WF, Forman SA: Coronary Drug Project: Methods and lessons of a multicenter clinical trial. Chapter 12 "External quality control programs." Controlled Clinical Trials 1983; 4:44166.
16. Forman S, Furberg C, Wenger NK, Stamler J. for the Coronary Drug Project Research Group: Blood pressure in survivors of myocardial infarction. J Am Coll Cardiol 1984; 4:113547.
17. TIMI Study Group. Thrombolysis in Myocardial Infarction (TIMI) Trials: Phase I findings. New Engl J Med 1985; 312:9326.
18. Hillis LD, and TIMI Principal Investigators: Highdose intravenous streptokinase for acute myocardial infarction: Preliminary results of a multicenter trial. J Am Coll Cardiol 1985; 6:95762.
19. Williams DO, and TIMI Principal Investigators: Intravenous recombinant tissue type plasminogen activator in acute myocardial infarction: A report from the NHLBI Thrombolysis in Myocardial Infarction (TIMI) Trial. Circulation 1986; 73:33846.
20. Chesebro JH, and TIMI Principal Investigators: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:1:14254.
21. Mueller HS, Rao AK, Forman S: Thrombolysis in Myocardial Infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue type plasminogen activator. J Am Coll Cardiol 1987; 10:47990.
22. Passamani E, and TIMI Investigators: The (TIMI) Thrombolysis in Myocardial Infarction Phase II Pilot: Tissue plasminogen activator (rtPA) followed by percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Cardiol 1987; 10:5:51B-64B.
23. Williams DO, Ruocco NA, Forman S: Coronary angioplasty following tissuetype plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction Trial. J Am Coll Cardiol 1987; 10:5:45B-50B.
24. Knatterud GL, Forman, SA: Patient recruitment experience in the Thrombolysis in Myocardial Infarction Trial. NHLBI Recruitment Workshop, April 1986. Controlled Clinical Trials 1987; 8:86S-93S.
25. Dalen DE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G: Six- and twelve-month follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Am J Cardiol 1988; 62:4:179-85.
26. Rogers WJ, Bourge RC, Papapietro SE, Wackers FHT, Zaret BL, Forman S, Dodge HT, Robertson TL, Passamani ER, Braunwald E, and TIMI Investigators: Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Pilot Study. Am J Cardiol 1989; 63:503-12.
27. Wackers JTH, Terrin ML, Kayden DS, Knatterud, GL, Forman S, Braunwald E, Zaret BL, and TIMI Investigators: Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. J Am Coll Cardiol 1989; 13:998-1005.
28. TIMI Study Group: Comparison of invasive and conservative strategies following intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. New Engl J Med 1989; 320:618-27.
29. Hillis LD, Forman S, Braunwald E, and the TIMI Investigators: Risk stratification in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1990; 16:313-5.
30. Roberts R, Rogers W, Mueller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E, Zaret BL, Wackers FJT, Braunwald E. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83:422-37.
31. Gore JM, Sloan M, Price TR, Randall AM, Bovill E, Collen D, Forman S, Knatterud G, Sopko G, Terrin ML. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma following acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study (TIMI II Pilot and Clinical Trial). Circulation 1991; 83:448-59.
32. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R, and the TIMI Investigators. Influence of coronary collateral vessels on myocardial infarct size in man: Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Circulation 1991; 83:739-46.
33. Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatterud GL, for the TIMI Investigators. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II: Predictors of Early Morbidity and Mortality. Circulation 1992; 85:1254-64.
34. Tofler GH, Muller JE, Stone PH, Forman S, Solomon RE, Knatterud GL, Braunwald E. and the TIMI Research Group. Modifiers of Timing and Possible Triggers of Acute Myocardial Infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI) Study Group. J Am Coll Cardiol 1992; 20:1049-55.
35. Terrin M, Williams DO, Kleiman NS, Willerson J, Mueller HS, Desvigne-Nickens P, Forman SA, Knatterud GL, Braunwald E, for the TIMI II Investigators. Two- and Three-Year Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Clinical Trial. J Am Coll Cardiol 1993; 22:1763-72.
36. Cox DA, Rogers WJ, Aguirre FV, Forman S, Solomon R and the TIMI Investigators. Presence or Absence of Chest Pain at Initiation of Lytic Therapy: Effect on Outcome in Acute MI. Am J Cardiol 1994; 73:729-36.
37. Pepine CJ, Geller NL, Knatterud GL, Bourassa MG, Chaitman BR, Davies RF, Day P, Deanfield JE, Goldberg AD, McMahon RP, Mueller H, Ouyang P, Pratt C, Proschan M, Rogers WJ, Selwyn AP, Sharaf B, Sopko G, Stone PH, Conti CR for the ACIP Investigators. The Asymptomatic Cardiac Ischemia Pilot (ACIP) study: Design of a randomized clinical trial, baseline data and implications for a long-term outcome trial. J Amer Coll Cardiol 1994; 24:1-10.
38. Knatterud GL, Bourassa MG, Pepine CJ, Geller NL, Sopko G, Chaitman BR, Pratt C, Stone PH, Davies RF, Rogers WJ, Deanfield JE, Goldberg AD, Ouyang P, Mueller H, Sharaf B, Day P, Selwyn AP, Conti CR for the ACIP Investigators. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. J Amer Coll Cardiol 1994: 11-20.
39. Sloan MA, Price TR, Petito C., Randall AMY, Solomon RE, Terrin ML, Gore J, Collen D, Kleiman N, Feit F, Babb J, Herman M, Roberts WC, Sopko G, Bovill E, Forman S, Knatterud GL for the TIMI Investigators. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The TIMI II pilot and randomized trial combined experience. Neurology 1995; 45:649-58.
40. Zaret BL, Wackers FJ, Terrin ML, Forman SA, Williams DO, Knatterud GL, Braunwald E. Value of radionuclide rest and exercise left ventricular ejection fraction to assess survival of patients following thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II Study. J Am Coll Cardiol 1995; 26:73-9.